Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Urothelial Carcinoma Treatment Companies

ID: MRFR/Pharma/4983-HCR
100 Pages
Rahul Gotadki
Last Updated: February 16, 2025
Urothelial carcinoma, also known as transitional cell carcinoma, is a type of cancer that arises in the urothelial cells lining the bladder, ureter, and other parts of the urinary system. The treatment landscape for urothelial carcinoma has evolved significantly in recent years, with various companies playing a pivotal role in developing innovative therapies to address this disease
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Top Industry Leaders in the Urothelial Carcinoma Treatment Market

Urothelial Carcinoma Treatment Market

Latest Urothelial Carcinoma Treatment Companies Updates

Janssen Receives FDA Approval for TECENTRIQ (Atezolizumab) in Combination with AVASTIN (Bevacizumab) for the First-Line Treatment of Patients with Unresectable Locally Advanced or

Metastatic Urothelial Carcinoma: This October 2023 approval expands treatment options for advanced bladder cancer patients.

AstraZeneca Announces Positive Phase III Results for Encorafenib and Cetuximab Combination Therapy for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: This promising development in November 2023 could lead to a new first-line treatment option.

Pfizer Initiates Phase III Trial Evaluating Bavencio (Velvalumab) Plus Chemotherapy as a First-Line Treatment for Muscle-Invasive Urothelial Carcinoma: This ongoing trial investigates another potential first-line therapy.

List ofย Urothelial Carcinoma Treatmentย Key companies in the market:

  • GlaxoSmithKline plc
  • Genentech, Inc
  • Novartis AG
  • Dendreon
  • Merck KGaA
  • Eisai Co
  • Sanofi S.A
  • Bristol-Myers Squibb